Insight into cardiovascular risk factors in patients with acromegaly

[1]  M. Ragonese,et al.  Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction , 2013, Endocrine.

[2]  A. Colao,et al.  Left ventricular synchronicity in acromegaly , 2013, Endocrine.

[3]  S. Moebus,et al.  Cardiac Risk in Patients with Treatment Naïve, First-Line Medically Controlled and First-Line Surgically Cured Acromegaly in Comparison to Matched Data from the General Population , 2011, Experimental and Clinical Endocrinology & Diabetes (Barth).

[4]  T. Meroño,et al.  GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly , 2012, Clinical endocrinology.

[5]  P. Chanson,et al.  A consensus on the diagnosis and treatment of acromegaly complications , 2012, Pituitary.

[6]  S. Polyzos,et al.  Oxidative Stress and Reduced Antioxidative Status, along with Endothelial Dysfunction in Acromegaly , 2012, Hormone and Metabolic Research.

[7]  A. Colao,et al.  Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. , 2011, European journal of endocrinology.

[8]  S. Melmed.  Acromegaly pathogenesis and treatment. , 2009, The Journal of clinical investigation.

[9]  G. Mazziotti,et al.  Diagnosis and treatment of acromegaly and its complications: consensus guidelines. , 2005, Journal of endocrinological investigation.

[10]  P. Marzullo,et al.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management. , 2004, Endocrine reviews.

[11]  S. Antoniu.  of a consensus guidelines , 2022 .